Post by Medical Device Network

GE HealthCare and Mayo Clinic are establishing a new research collaboration to advance personalised approaches to radioligand therapy (RLT) for advanced prostate cancer patients. RLT theranostics are a form of precision cancer treatment wherein a target molecule is combined with a therapeutic radioactive isotope. Administered intravenously, the drug class is designed to bind to specific proteins on cancer cells and deliver targeted radiation to destroy the tumour while minimising damage to healthy tissue. Under the pair-up, the two entities will initiate the Molecular Imaging Biomarker-Based End of Therapy Trial (MI-BET) study. Using GE HealthCare’s StarGuide SPECT/CT technology alongside MIM Software’s MIM LesionID Pro, the project aims to track how tumours are responding to treatment throughout therapy. MIM Software is a GE HealthCare company. Sergio Calvo, global general manager of theranostics at GE HealthCare, commented: “Making theranostics truly adaptive and personalised requires strong clinical evidence and a deeper understanding of how patients respond to therapy. “Through our collaboration with Mayo Clinic, we are exploring how imaging and data-driven insights can help inform more individualised treatment decisions, support the broader adoption of these approaches and contribute to the continued growth of precision care in oncology.” #theranostics #medicalimaging #RLTs #radioligands #precisiononcology Read the full report below: https://lnkd.in/eDHV3EjN